Table 2.
Clinical and demographic characteristics of the study participants in the SpA cohort
| mSpA | cSpA | |
| Patients, total | 33 | 75 |
| Females (%) | 16 (48.5) | 35 (46.7) |
| Age (years)±SD | 63.6±13.7 | 51.9±11.8 |
| CRP (mg/L)±SD | 3.5±3.6 | 6.5±14.8 |
| BMI (kg/m2)±SD | 27.1±5.0 | 28.5±5.7 |
| Malignancy characteristics: | ||
| Mean time since diagnosis (years)±SD | 10.5±9.4 | x |
| Malignancy type: | ||
| More than one malignancy (%) | 3 (9.1) | x |
| Melanoma (%) | 7 (21.2) | x |
| Breast cancer (%) | 6 (18.2) | x |
| Urogenital (%) | 10 (30.3) | x |
| Haematological (%) | 4 (12.1) | x |
| Others (%) | 9 (27.3) | x |
| Malignancy stage: | ||
| 0 (%) | 2 (6.1) | x |
| I (%) | 12 (36.4) | x |
| II (%) | 7 (21.2) | x |
| III (%) | 3 (9.1) | x |
| IV (%) | 3 (9.1) | x |
| Other classifications (%) | 2 (6.1) | x |
| N/A (%) | 6 (18.2) | x |
| Malignancy treatment: | ||
| Any therapy at time of SC (%) | 3 (9.1)* | x |
| Primary excision ever (%) | 29 (87.8) | x |
| Chemotherapy ever (%) | 7 (21.2) | x |
| Radiotherapy ever (%) | 5 (15.2) | x |
| Hormonal therapy ever (%) | 3 (9.1) | x |
| Immunotherapy ever (%) | 6 (18.2) | x |
| No therapy ever (%) | 2 (6.1) | x |
| Time since last cancer therapy: | ||
| Never treated | 2 (6.1) | |
| 0–6 months (%) | 4 (12.1) | x |
| 6 months to 5 years (%) | 11 (33.3) | x |
| >5 years (%) | 16 (48.6) | x |
| Current remission status: | ||
| Status available (%) | 33 (100.0) | x |
| Complete remission (%) | 27 (81.8) | x |
| Partial remission (%) | 2 (6.1) | x |
| Stable disease (%) | 2 (6.1) | x |
| Progressive disease (%) | 2 (6.1) | x |
| Relapse after SC | 1 (3.0) | x |
| Other malignancy after SC | 2 (6.1) | x |
| Autoimmunity characteristics: | ||
| Mean disease duration (years)±SD | 16.9±12.8 | 11.5±10.5 |
| Autoimmune arthritis type: | ||
| Psoriatic arthritis (%) | 22 (66.7) | 43 (57.3) |
| Other spondyloarthritis (%) | 11 (33.3) | 32 (42.6) |
| Serology: | ||
| HLA-B27 positive (%) | 8 (24.2) | 34 (45.3) |
| Autoimmune arthritis treatment (at SC): | ||
| GC (%) | 13 (39.4) | 20 (26.7) |
| Mean GC dosage (mg/day)±SD | 4.6±1.9 | 5.3±2.8 |
| csDMARDs (%) | 18 (54.5) | 36 (48.0) |
| Methotrexate (%) | 11 (33.3) | 29 (38.7) |
| Leflunomide (%) | 3 (9.1) | 10 (13.3) |
| Sulfasalazine (%) | 5 (15.2) | 4 (5.3) |
| other csDMARDs (%) | 11 (20.0) | 0 (0.0) |
| bDMARDs (%) | 15 (45.5) | 39 (52.0) |
| TNFi (%) | 12 (36.4) | 28 (37.3) |
| Other bDMARDs (%) | 3 (9.1) | 9 (12.0) |
| tsDMARDs (%) | 1 (3.0) | 0 (0.0) |
| Current remission status:† | ||
| Remission (%) | 13 (39.4) | 30 (40.0) |
| Low disease activity (%) | 9 (27.3) | 25 (33.3) |
| High disease activity (%) | 10 (30.3) | 20 (26.7) |
*Immunotherapy (n=1), chemotherapy (n=1) and hormonal therapy (n=1).
†Remission status as evaluated by attending physician.
BMI, body mass index; CRP, C reactive protein; cs/b/tsDMARD, conventional synthetic or biological or targeted synthetic disease-modifying antirheumatic drugs; cSPA, SpA without cancer; GC, glucocorticoids; HLA-B27, human leucocyte antigen class I molecule B27; mSPA, SpA with history of invasive cancer; SC, sample collection timepoint; SpA, spondyloarthritis; TNFi, tumour necrosis factor inhibitors.